Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash & Equivalents (2023 - 2025)

Immunome's Cash & Equivalents history spans 3 years, with the latest figure at $653.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 355.86% year-over-year to $653.5 million; the TTM value through Dec 2025 reached $653.5 million, up 355.86%, while the annual FY2025 figure was $653.5 million, 355.86% up from the prior year.
  • Cash & Equivalents reached $653.5 million in Q4 2025 per IMNM's latest filing, up from $272.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $653.5 million in Q4 2025 to a low of $38.4 million in Q2 2023.
  • Average Cash & Equivalents over 3 years is $194.5 million, with a median of $149.7 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: soared 507.16% in 2024, then fell 12.96% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $98.7 million in 2023, then soared by 45.27% to $143.4 million in 2024, then soared by 355.86% to $653.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Cash & Equivalents are $653.5 million (Q4 2025), $272.6 million (Q3 2025), and $143.9 million (Q2 2025).